Clearmind Medicine Inc. announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application. Allowed claims directed to using a primary amine aminoindan compound to regulate a binge behavior.

Covers primary amine aminoindan compounds besides 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule. This latest patent builds upon Clearmind's broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India. The granting of this latest patent establishes both the company's patent protection around its molecule as well as its extensive IP protection in the psychedelic space.

Clearmind's IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as theUS, Europe, China, and India. MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and exerts a slight euphoric, alcohol-like experience with potential to change the lives of millions who struggle to drink in moderation. Clearmind?s MEAI-based treatment focuses on Alcohol Use Disorder, which is incredibly common.

It varies from mild to excessive and is characterized by a person?s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Clearmind?s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.